Burning Rock Biotech (BNR) Common Equity (2019 - 2026)

Burning Rock Biotech (BNR) has reported Common Equity for 7 consecutive years, with $75.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Common Equity fell 6.67% year-over-year to $75.5 million; the TTM figure through Dec 2025 stood at $75.5 million (down 6.67% YoY), while the FY2025 annual figure was $76.5 million, down 3.81% from the prior year.
• Common Equity came in at $75.5 million for Q4 2025 at Burning Rock Biotech, down from $80.9 million in the prior quarter.
• The five-year high for Common Equity was $288.6 million in Q4 2021, with the low at $75.5 million in Q4 2025.
• Average Common Equity over 5 years is $154.7 million, with a median of $134.8 million recorded in 2022.
• Across the five-year window, Common Equity tumbled 43.57% in 2022 and slipped 6.67% in 2025, its largest moves.
• Year by year, Common Equity stood at $288.6 million in 2021, then sank by 43.57% to $162.9 million in 2022, then plunged by 34.47% to $106.7 million in 2023, then slipped by 24.23% to $80.9 million in 2024, then dropped by 6.67% to $75.5 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $75.5 million, $80.9 million, and $106.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.